TOI: BTIG Reiterates Buy Rating, Maintains $7 Price Target | TOI Stock News

robot
Abstract generation in progress

BTIG analyst David Larsen has reiterated a Buy rating for The Oncology Institute (TOI) and maintained a $7 price target, reflecting continued confidence in the stock. This comes after other analysts also initiated coverage with “Buy” ratings and similar price targets. Wall Street analysts forecast an average target price of $6.50 for TOI, suggesting a significant upside from its current price, though GuruFocus estimates a downside based on its fair value calculations.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin